Company: MYGN
Filing Date: 2025-04-09
Form Type: DEF 14A
Source: 0000899923-25-000028
Chunk: 11

Company: MYRIAD GENETICS INC
Filing Date: 2025-04-09
Form: DEF 14A
Chunk 11
---
 operating expenses as a percentage of revenue decreased from 72% in fiscal year 2023 to 68% in fiscal year 2024. (1)

(1) See reconciliation of adjusted operating income to GAAP operating loss, adjusted EBITDA to GAAP net loss, adjusted earnings (loss) per share to GAAP loss per share, and adjusted operating expenses to GAAP operating expenses in Appendix A.

Product Developments

• MyRisk Hereditary Cancer Test : We entered into a strategic partnership with jscreen™, a national organization that delivers education and access to genetic testing with a focus on high-risk populations. The collaboration combines our high-quality hereditary cancer and reproductive genetics products, MyRisk with RiskScore and Foresight Carrier Screen, with jscreen’s trusted education and genetic care navigation program.

• Prequel Prenatal Screen : Launched early gestational age Prequel Prenatal Screen, which can be performed as early as eight weeks into pregnancy, which is the first and only prenatal cell-free DNA (cfDNA) screen that can be performed at this early gestational age.

• Foresight Carrier Screen : Launched the Universal Plus Panel for Foresight Carrier Screen, which screens up to 272 genes associated with serious inherited conditions.

• Precise Tumor Test : We acquired select assets from Intermountain Precision Genomics' laboratory business, including the Precise Tumor test, the Precise Liquid test, and a CLIA-certified laboratory.

• Precise Minimal Residual Disease : We established a number of research collaborations regarding the use of our Precise MRD test for breast cancer patients with leading cancer research institutions, including The University of Texas MD Anderson Cancer Center, the University of Rochester Medical Center, and the National Cancer Center Hospital East in Japan and a study partnership with Aptitude Health.

Leadership

• Senior Leadership Transition : As part of our ongoing succession planning process, on February 24, 2025, we announced that Paul J. Diaz, our President and Chief Executive Officer, will step down from those positions, and resign from the Company’s Board, effective on April 30, 2025. The Board has appointed Samraat S. Raha, our current Chief Operating Officer, to succeed Mr. Diaz as our President and Chief Executive Officer and member of the Board effective April 30, 2025. The Board of Directors also appointed Mark S. Verratti, our current Chief Commercial Officer, to succeed Mr. Raha as our Chief Operating Officer effective April